Varsha Iyer, Ph.D.
Varsha has deep experience in Clinical Pharmacology and DMPK across therapeutic areas, including oncology and rare genetic diseases. She joined us from Agios Pharmaceuticals, Inc. where she was the Senior Director, DMPK-Clinical Pharmacology, and played a key role in the development of PYRUKYND®, the first disease-modifying therapy for hemolytic anemia in adults with Pyruvate Kinase Deficiency, approved for use in the US and EU. Prior to that, Varsha had roles of increasing responsibility in Oncology Clinical Pharmacology at Novartis Pharmaceuticals, Inc., and served as the preclinical DMPK and early clinical pharmacology lead for SCEMBLIX®, which has subsequently been approved as a monotherapy for adults with Chronic Myeloid Leukemia in the US and EU. Varsha earned her Ph.D. in Pharmacology from the University of Houston, followed by five years of postdoctoral training in neuropharmacology, PK-PD and drug development, and holds a bachelor’s degree in pharmaceutical sciences from the University of Mumbai (Bombay).